

REFERENCES

Herbal Constituents, 2nd Edition 2021

Chapter 3

References: Synergy and Variability

1. Macías F, J Galindo, and J Galindo. Evolution and current status of ecological phytochemistry. *Phytochemistry* 2007; 68(22-24):2917-36.
2. Williamson E. Synergy: interactions within herbal medicines. *The European Phytojournal*. <http://www.escop.com/epj2pdfs/Williamson.pdf>. Accessed September 22, 2008.
3. Spinella M. The importance of pharmacological synergy in psychoactive herbal medicines. *Altern Med Rev* 2002; 7(2):130-7.
4. Miaorong P and L Jing. Correlativity analysis on detoxifying effect of Radix Glycyrrhizae on Radix Aconiti Preparata in Sini Decoction. Proc. 40th Anniversary Conference, Beijing University of Chinese Medicine, August 1996. pp. 28-30. Beijing University Press.
5. Liu R. Potential synergy of phytochemicals in cancer prevention: mechanism of action. *J Nutr* 2004; 134(12 Suppl):3479S-3485S.
6. Stermitz F et al. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnicarbin, a multidrug pump inhibitor. *Proc Natl Acad Sci USA* 2000; 97(4):1433-7.
7. Dentali S. The White Paper on Standardization of Botanical Products. From *AHPA's Guidance Documents for the Manufacture and Sale of Botanical Extracts*. Available from the American Herbal Products Association, ahpa.org. Accessed September 22, 2008.
8. Food and Drug Administration. 21 CFR Part 111. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements: final rule. *Federal Register*. June 25, 2007; 72(121):34751-958.
9. Azaz A et al. Composition and the *in vitro* antimicrobial activities of the essential oils of some *Thymus* species. *Z Naturforsch [C]* 2004; 59(1-2):75-80.
10. Loreto F et al. On the induction of volatile organic compound emissions by plants as consequence of wounding or fluctuations of light and temperature. *Plant, Cell & Environment* 2006; 29(9):1820-8.
11. Toussaint J, F Smith, and S Smith. Arbuscular mycorrhizal fungi can induce the production of phytochemicals in sweet basil irrespective of phosphorus nutrition. *Mycorrhiza* 2007; 17(4):291-7.
12. Gray D et al. Acute drought stress and plant age effects on alkalamide and phenolic acid content in purple coneflower roots. *Planta Med* 2003; 69(1):50-5.
13. Chaney R et al. Improved understanding of hyperaccumulation yields commercial phytoextraction and phytomining technologies. *J Environ Qual* 2007; 36(5):1429-43.

14. Galeas M et al. Seasonal fluctuations of selenium and sulfur accumulation in selenium hyperaccumulators and related nonaccumulators. *New Phytol* 2007; 173(3):517-25.
15. Sors T, D Ellis, and D Salt. Selenium uptake, translocation, assimilation and metabolic fate in plants. *Photosynth Res* 2005; 86(3):373-89.
16. Pervaiz S. Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol. *Drug Resist Updat* 2004; 7(6):333-44.
17. Bavaresco L et al. Effect of ochratoxin A-producing *Aspergilli* on stilbenic phytoalexin synthesis in grapes. *J Agric Food Chem* 2003; 51(21):6151-7.
18. Jing P. Effects of growing conditions on purple corn cob (*Zea mays* L.) anthocyanins. *J Agric Food Chem* 2007; 55(21):8625-9.
19. de Vasconcelos Silva M et al. Chemical variation during daytime of constituents of the essential oil of *Ocimum gratissimum* leaves. *Fitoterapia* 1999; 70(1):32-4.
20. Bisset N et al. (Eds.), 1994. *Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis*. Boca Raton, FL: CRC Press. pp. 486-89.
21. Kocsis L, P Liebhard, and W Praznik. Effect of seasonal changes on content and profile of soluble carbohydrates in tubers of different varieties of Jerusalem artichoke (*Helianthus tuberosus* L.). *J Agric Food Chem* 2007; 55(23):9401-8.
22. Sibao C et al. Seasonal variations in the isoflavonoids of radix Puerariae. *Phytochem Anal* 2007; 18(3):245-50.
23. Schütz K, R Carle, and A Schieber. *Taraxacum*-a review on its phytochemical and pharmacological profile. *J Ethnopharmacol* 2006; 107(3):313-23.
24. Couet C, C Crews, and A Hanley. Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (*Symphytum officinale*). *Nat Toxins* 1996; 4(4):163-7.
25. AHP releases white paper on standardization of herbal product. *HerbalGram* 2003; 60:12.

Chapter 5

References: Carbohydrates

1. Teff K et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. *J Clin Endocrinol Metab* 2004; 89(6):2963-72.
2. Bantle J et al. Effects of dietary fructose on plasma lipids in healthy subjects. *Am J Clin Nutr* 2000; 72:1128-34.
3. Havel P et al. Short-term and long-term consumption of high fructose, but not high glucose diets, increases postprandial triglycerides and apo-lipoprotein-B in women. *J Invest Med* 2003; 51(Suppl 1):S163.
4. Gaby A. Adverse effects of dietary fructose. *Altern Med Rev* 2005; 10(4):294-306.

5. Le K et al. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. *Am J Clin Nutr* 2006; 84(6):1374-79.
6. Le K et al. Metabolic effects of fructose. *Curr Opin Clin Nutr Metab Care* 2006; 9(4):469-75.
7. Pham T et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. *Am J Med Sci* 2007; 333(6):333-9.
8. Roberfroid M. Introducing inulin-type fructans. *Br J Nutr* 2005; 93(Suppl. 1):S13-S25.
9. Roberfroid M. Dietary fiber, inulin, and oligofructose: a review comparing their physiological effects. *Crit Rev Food Sci Nutr* 1993; 33(2):103-48.
10. Beylot M. Effects of inulin-type fructans on lipid metabolism in man and in animal models. *Br J Nutr* 2005; 93(Suppl. 1):S163-S168.
11. Watzl B et al. Inulin, oligofructose, and immunomodulation. *Br J Nutr* 2005; 93(Suppl. 1):S49-S55.
12. Weaver C. Inulin, oligofructose and bone health: experimental approaches and mechanisms. *Br J Nutr* 2005; 93(Suppl. 1):S99-103.
13. Pool-Zobel B. Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data. *Br J Nutr* 2005; 93(Suppl. 1):S73-90.
14. Ewaschuk J and L Dieleman. Probiotics and prebiotics in chronic inflammatory bowel diseases. *World J Gastroenterol* 2006; 12(37):5941-50.
15. Petchetti L et al. Nutraceuticals in cardiovascular disease: psyllium. *Cardiol Rev* 2007; 15(3):116-22.
16. Erkkila A and A Lichtenstein. Fiber and cardiovascular disease risk: how strong is the evidence? *J Cardiovasc Nurs* 2006; 21(1):3-8.
17. Eliaz I et al. The effect of modified citrus pectin on urinary excretion of toxic elements. *Phytother Res* 2006; 20:859-64.
18. Egger S et al. Studies on optimal dose and administration schedule of a hematopoietic stimulatory beta-(1,4)-linked mannan. *Int J Immunopharmacol* 1996; 18(2):113-26.
19. Egger S et al. Hematopoietic augmentation by a beta-(1,4)-linked mannan. *Cancer Immunol Immunother* 1996; 43(4):195-205.
20. Hetland G et al. Protective effect of *Plantago major* L. Pectin polysaccharide against systemic *Streptococcus pneumoniae* infection in mice. *Scand J Immunol* 2000; 52(4):348-55.
21. Pillai S et al. Use of quantitative flow cytometry to measure ex vivo immunostimulant activity of Echinacea: the case for polysaccharides. *J Altern Complement Med* 2007; 13(6):625-34.
22. Goel V. A proprietary extract from the echinacea plant (*Echinacea purpurea*) enhances systemic immune response during a common cold. *Phytother Res* 2005; 19(8):689-94.
23. Sharma M et al. *Phytother Res* 2006; 20(2):147-52.
24. Kim L. Immunological activity of larch arabinogalactan and Echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. *Altern Med Rev* 2002; 7(2):138-49.

25. Wasser S. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. *Appl Microbiol Biotechnol* 2002; 60:258-74.
26. Sullivan R, J Smith, and N Rowan. Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. *Perspect Biol Med* 2006; 49(2):159-70.
27. Kardosova A and E Machova. Antioxidant activity of medicinal plant polysaccharides. *Fitoterapia* 2006; 77:367-73.
28. Kiyohara H et al. The presence of natural human antibodies reactive against pharmacologically active pectic polysaccharides from herbal medicines. *Phytomedicine* 2006; 13:494-500.
29. Li X. Effect of the *Lycium barbarum* polysaccharides on age-related oxidative stress in aged mice. *J Ethnopharmacol* 2007; 111:504-11.
30. Assinewe V et al. Extractable polysaccharides of *Panax quinquefolius* L. (North American Ginseng) root stimulate TNF α production by alveolar macrophages. *Phytomedicine* 2002; 9:398-404.
31. Park E et al. Water-soluble polysaccharide from *Eleutherococcus senticosus* stems attenuates fulminant hepatic failure induced by D-galactosamine and lipopolysaccharide in mice. *Basic Clin Pharmacol Toxicol* 2004; 94(6):298-304.
32. Kulichenko L et al. A randomized, controlled study of KanJang versus amantadine in the treatment of influenza in Volgograd. *J Herb Pharmacother* 2003; 3:77-93.
33. Bradbury J. The acidity of raphides from the edible aroids. *J Sci Food Agric* 1998; 76:608-16.
34. Guil J et al. Oxalic acid and calcium determination in wild edible plants. *J Agric. Food Chem* 1996; 44:1821-3.
35. Farook N. Inhibition of mineralization of urinary stone forming minerals by medicinal plants. *E-Journal of Chemistry* 2006; 3(12):182-5.
36. Reig R. Fatal poisoning by *Rumex crispus* (curled dock): pathological findings and application of scanning electron microscopy. *Vet Hum Toxicol* 1990; 32(5):468-70.
37. Massey L, M Liebman, and S Kynast-Gales. Ascorbate increases human oxaluria and kidney stone risk. *J Nutr* 2005; 135:1673-7.
38. Heilburg I. Renal stone disease: causes, evaluation, and medical treatment. *Arq Bras Endocrinol Metab* 2006; 50(4):823-31.
39. Lieske J. Use of a probiotic to decrease enteric hyperoxaluria. *Kidney Int* 2005; 68(3):1244-9.
40. Nishiura J. Effect of calcium intake on urinary oxalate excretion in calcium stone-forming patients. *Braz J Med Biol Res* 2002; 35:669-75.
41. Chai W and M Leibman. Effect of different cooking methods on vegetable oxalate content. *J Agric Food Chem* 2005; 53(8):3027-30.
42. Santamaria P et al. A survey of nitrate and oxalate content in fresh vegetables. *J Sci Food Agric* 1999; 79:1882-8.

43. Thakur M, M Kumari, and C Pundir. Determination of oxalate in foodstuffs with arylamine glass-bound oxalate oxidase and peroxidase. *Curr Sci* 2001; 81(3):248-51.
44. Fu H et al. Identification of oxalic acid and tartaric acid as major persistent pain-inducing toxins in the stinging hairs of the nettle, *Urtica thunbergiana*. *Ann Bot (Lond)* 2006; 98:57-65.
45. Ozen T and H Korkmaz. Modulatory effect of *Urtica dioica* L. (Urticaceae) leaf extract on biotransformation enzyme systems, antioxidant enzymes, lactate dehydrogenase and lipid peroxidation in mice. *Phytomedicine* 2003; 10: 405-15.
46. Randall C et al. Randomized controlled trial of nettle sting for treatment of base-of-thumb pain. *J R Soc Med* 2000; 93:305-30.

Chapter 6

References: Lipids

1. Menendez J and R Lupu. Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9). *Curr Pharm Biotechnol* 2006; 7(6):495-502.
2. Devaraj S, S Kasim-Karakas, and I Jialal. The effect of weight loss and dietary fatty acids on inflammation. *Curr Atheroscler Rep* 2006; 8(6):477-86.
3. Basu A, S Devaraj, and I Jialal. Dietary factors that promote or retard inflammation. *Arterioscler Thromb Vasc Biol* 1998; 26(5):995-1001.
4. Yaqoob P. Monounsaturated fatty acids and immune function. *Eur J Clin Nutr* 2002; 56 Suppl 3:S9-S13.
5. Nestel P, P Clifton, and M Noakes. Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men. *J Lipid Res* 1994; 35(4):656-62.
6. Garg M, R Blake, and R Wills. Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. *J Nutr* 2003; 133(4):1060-3.
7. Hiraoka-Yamamoto J et al. Serum lipid effects of a monounsaturated (palmitoleic) Fatty acid-rich diet based on macadamia nuts in healthy, young Japanese women. *Clin Exp Pharmacol Physiol* 2004; 31 Suppl 2:S37-8.
8. Hyson D, B Schneeman, and P Davis. Almonds and almond oil have similar effects on plasma lipids and LDL oxidation in healthy men and women. *J Nutr* 2002; 132(4):703-7.
9. Garg et al. Macadamia nut consumption modulates favourably risk factors for coronary artery disease in hypercholesterolemic subjects. *Lipids* 2007; 42(6):583-7.
10. Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? *Int J Vitam Nutr Res* 1998; 68(3):159-73.

11. Griel A et al. An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. *Nutr J* 2007; 6:2.
12. Erasmus U. 1993. *Fats that Heal, Fats that Kill*. 2nd Ed. Burnaby, BC: Alive Books.
13. Ursin V. Modification of plant lipids for human health: development of functional land-based omega-3 fatty acids. *J Nutr* 2003; 133(12):4271-4.
14. Pischon T et al. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. *Circulation* 2003; 108(2):155-60.
15. Griel A et al. An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. *Nutr J* 2007; 6:2.
16. Weiss L, E Barrett-Connor, and D von Muhlen. Ratio of n_6 to n_3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study. *Am J Clin Nutr* 2005; 81:934-8.
17. Hogstrom M et al. n-3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO₂ Study. *Am J Clin Nutr* 2007; 85(3):803-7.
18. Kruger M et al. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. *Aging (Milano)* 1998; 10:385-94.
19. Zhao G et al. Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. *J Nutr* 2004; 134:2991-7.
20. Le Jossic-Corcus C et al. Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids. *Biochem J* 2005; 385(Pt 3):787-94.
21. Assies J et al. Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study. *Prostaglandins Leukot Essent Fatty Acids* 2004; 70:349-56.
22. Logan A. Omega-3 fatty acids and major depression: A primer for the mental health professional. *Lipids in Health and Disease* 2004; 3:25.
23. Sorgi P et al. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. *Nutrition Journal* 2007; 6:16.
24. Cangemi F. TOZAL Study: An open case control study of an oral antioxidant and omega-3 supplement for dry AMD. *BMC Ophthalmology* 2007; 7:3.
25. Carpentier Y, L Portois, and W Malaisse. Fatty acids and the metabolic syndrome. *Am J Clin Nutr* 2006; 83(suppl):S1499-504.
26. Oda E. n-3 Fatty acids and the endocannabinoid system. *Am J Clin Nutr* 2007; 85(3):919-23.
27. Haag M and N Dippenaar. Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection. *Med Sci Monit* 2005; 11(12):RA359-67.
28. Mozaffarian D et al. *Trans* fatty acids and cardiovascular disease. *N Engl J Med* 2006; 354(15):1601-13.
29. Lopez-Garcia E et al. Consumption of *trans* fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. *J Nutr* 2005; 135(3):562-6.

30. Baer D et al. Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. *Am J Clin Nutr* 2004; 79(6):969-73.
31. Haag M and N Dippenaar. Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection. *Med Sci Monit* 2005; 11(12):RA359-67.
32. Larqué E et al. Dietary *trans* fatty acids alter the compositions of microsomes and mitochondria and the activities of microsome delta6-fatty acid desaturase and glucose-6-phosphatase in livers of pregnant rats. *J Nutr* 2003; 133(8):2526-31.
33. Kraft J et al. The conversion efficiency of *trans*-11 and *trans*-12 18:1 by Δ 9-desaturation differs in rats. *J Nutr* 2006; 136(5):1209-14.
34. Mensink R et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr* 2003; 77(5):1146-55.
35. Lopez-Garcia E et al. Consumption of *trans* fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. *J Nutr* 2005; 135(3):562-6.
36. Lemaitre R et al. Cell membrane *trans*-fatty acids and the risk of primary cardiac arrest. *Circulation* 2002; 105(6):697-701.
37. Loi C et al. Incorporation and metabolism of dietary *trans* isomers of linolenic acid alter the fatty acid profile of rat tissues. *J Nutr* 2000; 130(10):2550-5.
38. Wahle K et al. Conjugated linoleic acids: are they beneficial or detrimental to health? *Prog Lipid Res* 2004; (6):553-87.
39. Karupaiah T and K Sundram. Effects of stereospecific positioning of fatty acids in triacylglycerol structures in native and randomized fats: a review of their nutritional implications. *Nutrition & Metabolism* 2007; 4:16.
40. St-Onge M and P Jones. Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity. *J Nutr* 2002; 132(3):329-32.
41. Beermann C et al. Short term effects of dietary medium-chain fatty acids and n-3 long-chain polyunsaturated fatty acids on the fat metabolism of healthy volunteers. *Lipids Health Dis* 2003; 2:10.
42. Lichtenberger L et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. *Nat Med* 1995; 1(2):154-8.
43. Kumar R and O Katare. Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: a review. *AAPS PharmSciTech* 2005; 6(2):E298-310.
44. Cenacchi T et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. *Aging (Milano)* 1993; 5(2):123-33.
45. Delwaide P et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. *Acta Neurol Scand* 1986; 73(2):136-40.

46. Engel R et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. *Eur Neuropsychopharmacol* 1992; 2(2):149-55.
47. Habashy R et al. Anti-inflammatory effects of jojoba liquid wax in experimental models. *Pharmacol Res* 2005; 51(2):95-105.
48. Woelkart K et al. Bioavailability and pharmacokinetics of alkamides from the roots of *Echinacea angustifolia* in humans. *J Clin Pharmacol* 2005; 45(6):683-9.
49. Chen Y et al. Macrophage activating effects of new alkamides from the roots of *Echinacea* species. *J Nat Prod* 2005; 68(5):773-6.
50. Senchina D et al. Year-and-a-half old, dried *Echinacea* roots retain cytokine-modulating capabilities in an *in vitro* human older adult model of influenza vaccination. *Planta Med* 2006; 72(13):1207-15.
51. Kraus G et al. The synthesis and natural distribution of the major ketone constituents in *Echinacea pallida*. *Molecules* 2007; 12(3):406-14.
52. Raduner S et al. Alkylamides from *Echinacea* are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. *J Biol Chem* 2006; 281(20):14192-206.
53. Sugai E et al. Pungent qualities of sanshool-related compounds evaluated by a sensory test and activation of rat TRPV1. *Biosci Biotechnol Biochem* 2005; 69(10):1951-7.
54. Ley J et al. Structure activity relationships of trigeminal effects for artificial and naturally-occurring alkamides related to spilanthol. 11th Weurmann Flavour Research Symposium, 21-24 June, 2005, Roskilde, Denmark.
55. Rukachaisirikul T et al. Chemical constituents and bioactivity of *Piper sarmentosum*. *J Ethnopharmacol* 2004; 93(2-3):173-6.
56. Reddy S et al. Antibacterial constituents from the berries of *Piper nigrum*. *Phytomedicine* 2004; 11(7-8):697-700.
57. Kraus G et al. The synthesis and natural distribution of the major ketone constituents in *Echinacea pallida*. *Molecules* 2007; 12(3):406-14.
58. Bauer R, I Khan, and H Wagner. TLC and HPLC analysis of *Echinacea pallida* and *E. angustifolia* roots 1. *Planta Med* 1988; 54(5):426-430.
59. Zidorn C et al. Polyacetylenes from the Apiaceae vegetables carrot, celery, fennel, parsley, and parsnip and their cytotoxic activities. *J Agric Food Chem* 2005; 53(7):2518-23.
60. Pellati F et al. Isolation and structure elucidation of cytotoxic polyacetylenes and polyenes from *Echinacea pallida*. *Phytochemistry* 2006; 67(13):1359-64.
61. Christensen L and K Brandt. Bioactive polyacetylenes in food plants of the Apiaceae family: occurrence, bioactivity, and analysis. *J Pharm Biomed Anal* 2006; 41(3):683-93.
62. Kwon B et al. Polyacetylene analogs, isolated from hairy roots of *Panax ginseng*, inhibit Acyl-CoA:cholesterol acyltransferase. *Planta Med* 1997; 63(6):552-3.

63. Yang M et al. Polyacetylenes from the roots of cultivated-wild ginseng and their cytotoxicity *in vitro*. *Arch Pharm Res* 2008; 31(2):154-9.
64. Johnson W. Many drugs and phytochemicals can be activated to biological reactive intermediates. *Curr Drug Metab* 2008; 9(4):344-51.

Chapter 7

References: Amino Acids and Derivatives

1. Bukowski J and S Percival. L-theanine intervention enhances human gammadeltaT lymphocyte function. *Nutr Rev* 2008; 66(2):96-102.
2. Kamath A et al. Antigens in tea-beverage prime human V γ 2V δ 2 T cells *in vitro* and *in vivo* for memory and nonmemory antibacterial cytokine responses. *Proc Natl Acad Sci U S A* 2003; 100(10):6009-14.
3. Nathan P et al. The neuropharmacology of L-theanine (N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. *J Herb Pharmacother* 2006; 6(2):21-30.
4. Rogers P et al. Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. *Psychopharmacology (Berl)* 2008; 195(4):569-77.
5. Turner E, J Loftis, and A Blackwell A. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. *Pharmacol Ther* 2006; 109(3):325-38.
6. Lowe S et al. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI. *Psychoneuroendocrinology* 2006; 31(4):473-84.
7. Fu H et al. Identification of oxalic acid and tartaric acid as major persistent pain-inducing toxins in the stinging hairs of the Nettle, *Urtica thunbergiana*. *Annals of Botany* 2006; 98:57-65.
8. Abourashed E. Ephedra in perspective-a current review. *Phytotherapy Research* 2003; 17:703-12.
9. Li X et al. The potential use of Chinese herbal medicines in treating allergic asthma. *Ann Allergy Asthma Immunol* 2004; 93(2 Suppl 1):S35-44.
10. Lee R and M Balick. Chocolate: Healing 'food of the gods'? *Alternative Therapies* 2001; 7(5):120-2.
11. Livingston M and H Livingston. Monoamine oxidase inhibitors. An update on drug interactions. *Drug Saf* 1996; 14(4):219-27.
12. D'Andrea G et al. Biochemistry of neuromodulation in primary headaches: focus on anomalies of tyrosine metabolism. *Neurol Sci* 2007; 28 Suppl 2:S94-6.
13. Chandra A et al. Goitrogenic content of Indian cyanogenic plant foods & their *in vitro* anti-thyroidal activity. *Indian J Med Res* 2004; 119:180-5.
14. Higdon J et al. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. *Pharmacol Res* 2007; 55(3):224-36.

15. Juge N, R Mithen, and M Traka. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. *Cell Mol Life Sci* 2007; 64(9):1105-27.
16. Wan J and D Diaz-Sanchez. Antioxidant enzyme induction: a new protective approach against the adverse effects of diesel exhaust particles. *Inhal Toxicol* 2007; 19 Suppl 1:177-82.
17. Ankri S and D Mirelman. Antimicrobial properties of allicin from garlic. *Microbes Infect* 1999; 1(2):125-9.
18. Davis S. An overview of the antifungal properties of allicin and its breakdown products- the possibility of a safe and effective antifungal prophylactic. *Mycoses* 2005; 48(2):95-100.
19. Seki T et al. Anticancer effects of diallyl trisulfide derived from garlic. *Asia Pac J Clin Nutr* 2008; 17 Suppl 1:249-52.
20. Shaik I et al. Protective effects of diallyl sulfide, a garlic constituent, on the warm hepatic ischemia-reperfusion injury in a rat model. *Pharm Res* 2008; 25(10):2231-42.
21. Ariga T and T Seki. Antithrombotic and anticancer effects of garlic-derived sulfur compounds: a review. *Biofactors* 2006; 26(2):93-103.
22. Reuter H, H Koch, and L Lawson. In: *Garlic: the Science and Therapeutic Application of Allium sativum L. and Related Species*. Koch H and L Lawson, Eds. Williams & Wilkins: Baltimore, 1996. pp. 135-212.
23. Wargovich M. Diallylsulfide and allylmethylsulfide are uniquely effective among organosulfur compounds in inhibiting CYP2E1 protein in animal models. *J Nutr* 2006; 136(3) Suppl:832S-834S.
24. Wu C et al. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. *J Agric Food Chem* 2002; 50(2):378-83.
25. Guyonnet D et al. Antimutagenic activity of organosulfur compounds from *Allium* is associated with phase II enzyme induction. *Mutat Res* 2001; 495(1-2):135-45.
26. Tilli C et al. The garlic-derived organosulfur component ajoene decreases basal cell carcinoma tumor size by inducing apoptosis. *Arch Dermatol Res* 2003; 295(3):117-23.
27. Ledezma E and R Apitz-Castro. Ajoene, the main active compound of garlic (*Allium sativum*): a new antifungal agent. *Rev Iberoam Micol* 2006; 23(2):75-80.
28. Reuter, 1996. p. 163.
29. Rose P et al. Bioactive S-alk(en)yl cysteine sulfoxide metabolites in the genus *Allium*: the chemistry of potential therapeutic agents. *Nat Prod Rep* 2005; 22(3):351-68.
30. Chu Q et al. A novel anticancer effect of garlic derivatives: inhibition of cancer cell invasion through restoration of E-cadherin expression. *Carcinogenesis* 2006; 27(11):2180-9.
31. Ban J et al. Inhibition of cell growth and induction of apoptosis via inactivation of NF-kappa B by a sulfur compound isolated from garlic in human colon cancer cells. *J Pharmacol Sci* 2007; 104(4):374-83.

32. Velmurugan B, V Bhuvaneshwari, and S Nagini. Effect of S-allylcysteine on oxidant-antioxidant status during N-methyl-N'-nitro-N-nitrosoguanidine and saturated sodium chloride-induced gastric carcinogenesis in Wistar rats. *Asia Pac J Clin Nutr* 2003; 12(4):488-94.
33. Aminari M et al. Cyanide-metabolizing enzyme rhodanese in human tissues: comparison with domestic animals. *Comparative Clinical Pathology* 2007; 16(1):47-51.
34. Simeonova F and L Fishbein. 2004. *Hydrogen Cyanide and Cyanides: Human Health Aspects*. World Health Organization. At INCHEM: <http://www.inchem.org/documents/cicads/cicads/cicad61.htm>. Accessed September 22, 2008.
35. Milazzo S, S Lejeune, and E Ernst. Laetrile for cancer: a systematic review of the clinical evidence. *Support Care Cancer* 2007; 15(6):583-95.
36. Felter H and J Lloyd. 1898. Aqua Laurocerasi Monograph. In: *King's American Dispensatory*. Online: http://www.henriettesherbal.com/eclectic/kings/prunus-laur_aqua.html. Accessed September 22, 2008.

Chapter 8

References: Polyphenols

1. Lanas A. Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications. *Postgrad Med* 2005; 117(6):23-8, 31.
2. Fries J. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. *J Rheumatol* 1991; 28:6-10.
3. Edderkaoui M et al. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. *World J Gastroenterol* 2008; 14(23):3672-80.
4. Larrosa M et al. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. *J Nutr Biochem* 2006; 17(9):611-25.
5. Bell C and S Hawthorne. Ellagic acid, pomegranate and prostate cancer - a mini review. *J Pharm Pharmacol* 2008; 60(2):139-44.
6. Mertens-Talcott S, S Talcott, and S Percival. Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. *J Nutr* 2003; 133:2669-74.
7. Chang W et al. Ellagic acid suppresses oxidised low-density lipoprotein-induced aortic smooth muscle cell proliferation: studies on the activation of extracellular signal-regulated kinase 1/2 and proliferating cell nuclear antigen expression. *Br J Nutr* 2008; 99(4):709-14.
8. Jagan S et al. Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. *Mol Cell Biochem* 2008; Epub Jul 16, 18629614.

9. Raina K et al. Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. *Mol Cancer Ther* 2008; 7(5):1258-67.
10. Park W et al. Cytotoxic effect of gallic acid on testicular cell lines with increasing H₂O₂ level in GC-1 spg cells. *Toxicol In Vitro* 2008; 22(1):159-63.
11. Ow Y and I Stupans. Gallic acid and gallic acid derivatives: effects on drug metabolizing enzymes. *Curr Drug Metab* 2003; 4(3):241-8.
12. Manach C et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr* 2005; 81(1 Suppl):230S-242S.
13. Felter H and J Lloyd. 1898. Acidum Gallicum (U.S.P.) Monograph. In: *King's American Dispensatory*. Online: <http://www.henriettesherbal.com/eclectic/kings/acidum-gall.html>. Accessed September 22, 2008.
14. Jiang R et al. Chemistry and biological activities of caffeic acid derivatives from *Salvia miltiorrhiza*. *Curr Med Chem* 2005; 12(2):237-46.
15. Barnes J et al. Echinacea species (*Echinacea angustifolia* (DC.) Hell., *Echinacea pallida* (Nutt.) Nutt., *Echinacea purpurea* (L.) Moench): a review of their chemistry, pharmacology and clinical properties. *J Pharm Pharmacol* 2005; 57(8):929-54.
16. Natarajan K et al. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. *Proc Natl Acad Sci U S A* 1996; 93(17):9090-5.
17. Greenberg J, C Boozer, and A Geliebter. Coffee, diabetes, and weight control. *Am J Clin Nutr* 2006; 84(4):682-93.
18. van Dam R. Coffee and type 2 diabetes: from beans to beta-cells. *Nutr Metab Cardiovasc Dis* 2006; 16(1):69-77.
19. Petersen M and M Simmonds. Rosmarinic acid. *Phytochemistry* 2003; 62(2):121-5.
20. Nolkemper S et al. Antiviral effect of aqueous extracts from species of the Lamiaceae family against Herpes simplex virus type 1 and type 2 *in vitro*. *Planta Med* 2006; 72(15):1378-82.
21. Sanchez-Medina A et al. Comparison of rosmarinic acid content in commercial tinctures produced from fresh and dried lemon balm (*Melissa officinalis*). *J Pharm Pharm Sci* 2007; 10(4):455-63.
22. Swarup P et al. Antiviral and anti-inflammatory effects of rosmarinic acid in an experimental murine model of Japanese encephalitis. *Antimicrob Agents Chemother* 2007; 51(9):3367-70.
23. Geuenich S et al. Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. *Retrovirology* 2008; 5:27.
24. Facino R et al. Echinacoside and caffeoyl conjugates protect collagen from free radical-induced degradation: a potential use of Echinacea extracts in the prevention of skin photodamage. *Planta Med* 1995; 61(6):510-4.

25. Wu Y et al. Protective effects of echinacoside on carbon tetrachloride-induced hepatotoxicity in rats. *Toxicology* 2007; 232(1-2):50-6.
26. Chen H et al. Echinacoside prevents the striatal extracellular levels of monoamine neurotransmitters from diminution in 6-hydroxydopamine lesion rats. *J Ethnopharmacol* 2007; 114(3):285-9.
27. Pellati F et al. Variability in the composition of antioxidant compounds in Echinacea species by HPLC. *Phytochem Anal* 2005; 16(2):77-85.
28. Birt D et al. Echinacea in infection. *Am J Clin Nutr* 2008; 87(2):488S-92S.
29. Stevenson L et al. Modulation of macrophage immune responses by Echinacea. *Molecules* 2005; 10(10):1279-85.
30. Shevtsov V et al. A randomized trial of two different doses of a SHR-5 *Rhodiola rosea* extract versus placebo and control of capacity for mental work. *Phytomedicine* 2003; 10(2-3):95-105.
31. Kucinskaite A et al. Evaluation of biologically active compounds in roots and rhizomes of *Rhodiola rosea* L. cultivated in Lithuania. *Medicina (Kaunas)* 2007; 43(6):487-94.
32. World Health Organization. 2008. 516. *Safrole (WHO Food Additives Series 16)*. Online at INCHEM: <http://www.inchem.org/documents/jecfa/jecmono/v16je22.htm>. Accessed September 22, 2008.
33. Prakash P and N Gupta. Therapeutic uses of *Ocimum sanctum* Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. *Indian J Physiol Pharmacol* 2005; 49(2):125-31.
34. Fylaktakidou K et al. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. *Curr Pharm Des* 2004; 10(30):3813-33.
35. Hoult J and M Payá. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. *Gen Pharmacol* 1996; 27(4):713-22.
36. Stanić G et al. HPLC analysis of esculin and fraxin in horse-chestnut bark (*Aesculus hippocastanum* L.). *Croatica Chemica Acta* 1999; 72(4):827-34.
37. Lee B et al. Anti-oxidative and photo-protective effects of coumarins isolated from *Fraxinus chinensis*. *Arch Pharm Res* 2007; 30(10):1293-301.
38. Whang W et al. Natural compounds, fraxin and chemicals structurally related to fraxin protect cells from oxidative stress. *Exp Mol Med* 2005; 37(5):436-46.
39. Pittler M and E Ernst. Horse chestnut seed extract for chronic venous insufficiency. *Cochrane Database Syst Rev* 2006; (1):CD003230.
40. Dharmananda S. Warfarin and Chinese Medicine. ITM Online: <http://www.itmonline.org/arts/warfarin.htm>. Accessed September 22, 2008.
41. Finkelstein E et al. An outbreak of phytophotodermatitis due to celery. *Int J Dermatol* 1994; 33(2):116-8.
42. Eickhorst K, V DeLeo, and J Csaposs. Rue the herb: *Ruta graveolens*-associated phytophototoxicity. *Dermatitis* 2007; 18(1):52-5.

43. Fujita T et al. Comparative evaluation of 12 immature citrus fruit extracts for the inhibition of cytochrome P450 isoform activities. *Biol Pharm Bull* 2008; 31(5):925-30.
44. Girenavar B et al. Grapefruit juice and its furocoumarins inhibits autoinducer signaling and biofilm formation in bacteria. *Int J Food Microbiol* 2008; 125(2):204-8.
45. Gasparro F. The role of PUVA in the treatment of psoriasis. Photobiology issues related to skin cancer incidence. *Am J Clin Dermatol* 2000; 1(6):337-48.
46. McNeely W and K Goa. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. *Drugs* 1998; 56(4):667-90.
47. Lacey K, L Duinslaeger, and A Vanderkelen. Burns induced by plants. *Burns* 1995; 21(7):542-3.
48. Adlercreutz H. Lignans and human health. *Crit Rev Clin Lab Sci* 2007; 44(5-6):483-525.
49. Dai Q et al. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. *Cancer Epidemiol Biomarkers Prev* 2002; 11:815-21.
50. Saarinen N et al. Role of dietary lignans in the reduction of breast cancer risk. *Mol Nutr Food Res* 2007; 51(7):857-66.
51. Hulten K et al. An incident case-referent study on plasma enterolactone and breast cancer risk. *Eur J Nutr* 2002; 41:168-76.
52. Lin X, B Switzer, and W Demark-Wahnefried. Effect of mammalian lignans on the growth of prostate cancer cell lines. *Anticancer Res* 2001; 21:3995-9.
53. Demark-Wahnefried W et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects of hormonal levels, prostate-specific antigen, and histopathological features. *Urology* 2001; 58:47-52.
54. McCann M et al. Role of mammalian lignans in the prevention and treatment of prostate cancer. *Nutr Cancer* 2005; 52(1):1-14.
55. Bommareddy A et al. Chemopreventive effects of dietary flaxseed on colon tumor development. *Nutr Cancer* 2006; 54(2):216-22.
56. Adlercreutz H. Phyto-oestrogens and cancer. *Lancet Oncol* 2002; 3:364-73.
57. Prasad K. A study on regression of hypercholesterolemic atherosclerosis in rabbits by flax lignan complex. *J Cardiovasc Pharmacol Ther* 2007; 12(4):304-13.
58. Velasquez M and S Bhathena. Dietary phytoestrogens: a possible role in renal disease protection. *Am J Kidney Dis* 2001; 37:1056-68.
59. Ranich T, S Bhathena, and M Velasquez. Protective effects of dietary phytoestrogens in chronic renal disease. *J Ren Nutr* 2001; 11:183-93.
60. Schottner M, G Spiteller, and D Gansser. Lignans interfering with 5 alpha-dihydrotestosterone binding to human sex hormone-binding globulin. *J Nat Prod* 1998; 61:119-21.
61. Haggans C et al. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. *Nutr Cancer* 1999; 33:188-95.

62. Hutchins A et al. Flaxseed consumption influences endogenous hormone concentrations in postmenopausal women. *Nutr Cancer* 2001; 39:58-65.
63. McCann S et al. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. *J Nutr* 2002; 132:3036-41.
64. Rosenberg Zand R, D Jenkins, and E Diamandis. Flavonoids and steroid hormone-dependent cancers. *J Chromatog B* 2002; 777:219-32.
65. Adlercreutz H et al. Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. *Lancet* 1982; 2:1295-9.
66. Nakano D et al. Dietary sesamin suppresses aortic NADPH oxidase in DOCA salt hypertensive rats. *Clin Exp Pharmacol Physiol* 2008; 35(3):324-6.
67. Utsunomiya T et al. Antioxidant and anti-inflammatory effects of a diet supplemented with sesamin on hepatic ischemia-reperfusion injury in rats. *Hepato gastroenterology* 2003; 50(53):1609-13.
68. Yamada Y et al. Dietary tocotrienol reduces UVB-induced skin damage and sesamin enhances tocotrienol effects in hairless mice. *J Nutr Sci Vitaminol (Tokyo)* 2008; 54(2):117-23.
69. Peñalvo J et al. Dietary sesamin is converted to enterolactone in humans. *J Nutr* 2005; 135(5):1056-62.
70. Tsuruoka N et al. Modulating effect of sesamin, a functional lignan in sesame seeds, on the transcription levels of lipid- and alcohol-metabolizing enzymes in rat liver: a DNA microarray study. *Biosci Biotechnol Biochem* 2005; 69(1):179-88.
71. Seeram N. Berry fruits for cancer prevention: current status and future prospects. *J Agric Food Chem* 2008; 56(3):630-5.
72. Arteaga S et al. *Larrea tridentata* (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. *J Ethnopharmacol* 2005; 98(3):231-9.
73. Plaza C et al. Inhibitory effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on respiration and growth of adenocarcinoma TA3 and its multiresistant variant TA3MTX-R. *In Vivo* 2008; 22(3):353-61.
74. Cui Y et al. Nordihydroguaiaretic acid restores expression of silenced E-cadherin gene in human breast cancer cell lines and xenografts. *Anticancer Drugs* 2008; 19(5):487-94.
75. Ryan C et al. Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. *Prostate* 2008; 68(11):1232-40.
76. Lambert J et al. Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. *Toxicol* 2002; 40(12):1701-8.
77. Mills S and K Bone. 2005. *The Essential Guide to Herbal Safety*. St. Louis, MO: Elsevier. pp. 329-32.

78. Panossian A and G Wikman. Pharmacology of *Schisandra chinensis* Bail.: An overview of Russian research and uses in medicine. *J Ethnopharmacol* 2008; 118(2):183-212.
79. American Botanical Council. Intravenous milk thistle compound used to save victims of poisonous mushrooms. *HerbalGram* 2007; 74:16.
80. Aggarwal B et al. Curcumin: the Indian solid gold. *Adv Exp Med Biol* 2007; 595:1-75.
81. Rai D et al. Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. *Biochem J* 2008; 410(1):147-55.
82. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of turmeric (*Curcuma longa*). *J Altern Complement Med* 2003; 9(1):161-8.
83. Jacob A. Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. *PPAR Res* 2007; 2007:89369.
84. Osawa T. Nephroprotective and hepatoprotective effects of curcuminoids. *Adv Exp Med Biol* 2007; 595:407-23.
85. Lee H et al. Neuroprotective effect of curcumin is mainly mediated by blockade of microglial cell activation. *Pharmazie* 2007; 62(12):937-42.
86. Hsu Y et al. Curcuminoids-cellular uptake by human primary colon cancer cells as quantitated by a sensitive HPLC assay and its relation with the inhibition of proliferation and apoptosis. *J Agric Food Chem* 2007; 55(20):8213-22.
87. Joe B, M Vijaykumar, and B Lokesh. Biological properties of curcumin-cellular and molecular mechanisms of action. *Crit Rev Food Sci Nutr* 2004; 44(2):97-111.
88. Chrubasik S, M Pittler, and B Roufogalis. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. *Phytomedicine* 2005; 12(9):684-701.
89. Nurtjahja-Tjendraputra E et al. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. *Thromb Res* 2003; 111(4-5):259-65.
90. Shukla Y and M Singh. Cancer preventive properties of ginger: a brief review. *Food Chem Toxicol* 2007; 45(5):683-90.
91. Pan M et al. 6-Shogaol induces apoptosis in human colorectal carcinoma cells via ROS production, caspase activation, and GADD 153 expression. *Mol Nutr Food Res* 2008; 52(5):527-37.
92. Rhode J et al. Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. *BMC Complement Altern Med* 2007; 7:44.
93. Bernstein J. Capsaicin and substance P. *Clin Dermatol* 1991; 9(4):497-503.
94. Knotkova H, M Pappagallo, and A Szallasi. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? *Clin J Pain* 2008; 24(2):142-54.
95. Aggarwal B and S Shishodia. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. *Ann N Y Acad Sci* 2004; 1030:434-41.
96. Metzler M. Metabolism of stilbene estrogens and steroidal estrogens in relation to carcinogenicity. *Arch Toxicol* 1984; 55(2):104-9.

97. Newbold R. Prenatal exposure to diethylstilbestrol (DES). *Fertil Steril* 2008; 89(2 Suppl):e55-6.
98. Pirola L and S Fröjdö. Resveratrol: one molecule, many targets. *IUBMB Life* 2008; 60(5):323-32.
99. Labinskyy N et al. Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. *Curr Med Chem* 2006; 13(9):989-96.
100. Olas B and B Wachowicz. Resveratrol, a phenolic antioxidant with effects on blood platelet functions. *Platelets* 2005; 16(5):251-60.
101. Cal C et al. Resveratrol and cancer: chemoprevention, apoptosis, and chemosensitizing activities. *Curr Med Chem Anticancer Agents* 2003; 3(2):77-93.
102. Le Corre L et al. Resveratrol and breast cancer chemoprevention: molecular mechanisms. *Mol Nutr Food Res* 2005; 49(5):462-71.
103. Greenson J, B Sanford, and D Monti. St. John's wort (*Hypericum perforatum*): a review of the current pharmacological, toxicological, and clinical literature. *Psychopharmacology* 2001; 153(4):402-14.
104. Sampath P and K Vijayaragavan. Ameliorative prospective of alpha-mangostin, a xanthone derivative from *Garcinia mangostana* against beta-adrenergic catecholamine-induced myocardial toxicity and anomalous cardiac TNF-alpha and COX-2 expressions in rats. *Exp Toxicol Pathol* 2008; 60(4-5):357-64.
105. Chen L, L Yang, and C Wang. Anti-inflammatory activity of mangostins from *Garcinia mangostana*. *Food Chem Toxicol* 2008; 46(2):688-93.
106. Pinto M, M Sousa, and M Nascimento. Xanthone derivatives: new insights in biological activities. *Curr Med Chem* 2005; 12(21):2517-38.
107. Hsu M et al. Inhibition of the arachidonic acid cascade by norathyriol via blockade of cyclooxygenase and lipoxygenase activity in neutrophils. *Naunyn Schmiedeberg's Arch Pharmacol* 2004; 369(5):507-15.
108. Mathews J et al. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones *in vivo* and *in vitro*. *Drug Metab Dispos* 2005; 33(10):1555-63.
109. Ma Y et al. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. *Drug Metab Dispos* 2004; 32(11):1317-24.
110. Pittler M and E Ernst. Kava extract for treating anxiety. *Cochrane Database Syst Rev* 2003; (1):CD003383.
111. Wruck C et al. Kavalactones protect neural cells against amyloid beta peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. *Mol Pharmacol* 2008; 73(6):1785-95.
112. Heimler D et al. Polyphenol content and antioxidative activity in some species of freshly consumed salads. *J Agric Food Chem* 2007; 55(5):1724-9.

113. Neuhouser M. Dietary flavonoids and cancer risk: evidence from human population studies. *Nutr Cancer* 2004; 50(1):1-7.
114. Santangelo C et al. Polyphenols, intracellular signalling and inflammation. *Ann Ist Super Sanita* 2007; 43(4):394-405.
115. Fimognari C, M Lenzi, and P Hrelia. Chemoprevention of cancer by isothiocyanates and anthocyanins: mechanisms of action and structure-activity relationship. *Curr Med Chem* 2008; 15(5):440-7.
116. Zafra-Stone S et al. Berry anthocyanins as novel antioxidants in human health and disease prevention. *Mol Nutr Food Res* 2007; 51(6):675-83.
117. Boumendjel A. Aurones: a subclass of flavones with promising biological potential. *Curr Med Chem* 2003; 10(23):2621-30.
118. Chin Y et al. Anti-oxidant constituents of the roots and stolons of licorice (*Glycyrrhiza glabra*). *J Agric Food Chem* 2007; 55(12):4691-7.
119. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. *Yakugaku Zasshi* 2000; 120(10):849-62.
120. Zanolini P and M Zavatti. Pharmacognostic and pharmacological profile of *Humulus lupulus* L. *J Ethnopharmacol* 2008; 116(3):383-96.
121. Zierau O et al. Antiandrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin. *Planta Med* 2003; 69(9):856-8.
122. Demeule M et al. Green tea catechins as novel antitumor and antiangiogenic compounds. *Curr Med Chem Anticancer Agents* 2002; 2(4):441-63.
123. Grassi D et al. Tea, flavonoids, and nitric oxide-mediated vascular reactivity. *J Nutr* 2008; 138(8):1554S-1560S.
124. Ikeda I. Multifunctional effects of green tea catechins on prevention of the metabolic syndrome. *Asia Pac J Clin Nutr* 2008; 17 Suppl 1:273-4.
125. Garg A et al. Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. *Phytother Res* 2001; 15(8):655-69.
126. Szent-Györgyi A. *Pysiol Chem* 1938; 225:126.
127. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. *Expert Rev Anti Infect Ther* 2006; 4(2):291-302.
128. Kanaze F et al. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. *Eur J Clin Nutr* 2007; 61(4):472-7.
129. Benavente-García O et al. Beneficial action of *Citrus* flavonoids on multiple cancer-related biological pathways. *Curr Cancer Drug Targets* 2007; 7(8):795-809.
130. Kim Y et al. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production. *Br J Pharmacol* 2008; 154(1):165-73.
131. Shin Y et al. *In vitro* and *in vivo* antiallergic effects of *Glycyrrhiza glabra* and its components. *Planta Med* 2007; 73(3):257-61.

132. Asl M and H Hosseinzadeh. Review of pharmacological effects of *Glycyrrhiza* spp. and its bioactive compounds. *Phytother Res* 2008; 22(6):709-24.
133. Mersereau J et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. *Mol Cell Endocrinol* 2008; 283(1-2):49-57.
134. Graf B, P Milbury, and J Blumberg. Flavonols, flavones, flavanones, and human health: epidemiological evidence. *J Med Food* 2005; 8(3):281-90.
135. Zhang Q, X Zhao, and Z Wang. Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. *Food Chem Toxicol* 2008; 46(6):2042-53.
136. Yang S et al. Luteolin induces apoptosis in oral squamous cancer cells. *J Dent Res* 2008; 87(4):401-6.
137. Chiu F and J Lin. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. *Prostate* 2008; 68(1):61-71.
138. Kim J et al. Caspase activation and extracellular signal-regulated kinase/Akt inhibition were involved in luteolin-induced apoptosis in Lewis lung carcinoma cells. *Ann N Y Acad Sci* 2007; 1095:598-611.
139. Lim do Y et al. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. *Am J Physiol Gastrointest Liver Physiol* 2007; 292(1):G66-75.
140. Hu C and D Kitts. Antioxidant, prooxidant, and cytotoxic activities of solvent-fractionated dandelion (*Taraxacum officinale*) flower extracts *in vitro*. *J Agric Food Chem* 2003; 51(1):301-10.
141. Kim E et al. Flavonoids protect against cytokine-induced pancreatic beta-cell damage through suppression of nuclear factor kappaB activation. *Pancreas* 2007; 35(4):e1-9.
142. Verbeek R et al. The flavones luteolin and apigenin inhibit *in vitro* antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cells. *Biochem Pharmacol* 2004; 68(4):621-9.
143. Choi J et al. Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: role of nuclear factor-kappa B. *J Nutr* 2004; 134(5):1013-9.
144. Woźniak D, E Lamer-Zarawska, and A Matkowski. Antimutagenic and antiradical properties of flavones from the roots of *Scutellaria baicalensis georgi*. *Nahrung* 2004; 48(1):9-12.
145. Huang W, A Lee, and C Yang. Antioxidative and anti-inflammatory activities of polyhydroxyflavonoids of *Scutellaria baicalensis* GEORGI. *Biosci Biotechnol Biochem* 2006; 70(10):2371-80.
146. Ye F et al. Anticancer activity of *Scutellaria baicalensis* and its potential mechanism. *J Altern Complement Med* 2002; 8(5):567-72.

147. Ye F et al. Molecular mechanism of anti-prostate cancer activity of *Scutellaria baicalensis* extract. *Nutr Cancer* 2007; 57(1):100-10.
148. Kowalczyk E et al. Pharmacological effects of flavonoids from *Scutellaria baicalensis*. *Przegl Lek* 2006; 63(2):95-6.
149. Boots A, G Haenen, and A Bast. Health effects of quercetin: from antioxidant to nutraceutical. *Eur J Pharmacol* 2008; 585(2-3):325-37.
150. Harwood M et al. A critical review of the data related to the safety of quercetin and lack of evidence of *in vivo* toxicity, including lack of genotoxic/carcinogenic properties. *Food Chem Toxicol* 2007; 45(11):2179-205.
151. Okamoto T. Safety of quercetin for clinical application (Review). *Int J Mol Med* 2005; 16(2):275-8.
152. Slimestad R, T Fossen, and I Vågen. Onions: a source of unique dietary flavonoids. *J Agric Food Chem* 2007; 55(25):10067-80.
153. Terao J, Y Kawai, and K Murota. Vegetable flavonoids and cardiovascular disease. *Asia Pac J Clin Nutr* 2008; 17 Suppl 1:291-3.
154. Lee S et al. Hyperin, an aldose reductase inhibitor from *Acanthopanax senticosus* leaves. *Korean Society of Pharmacognosy* 2003; 9(1):4-6.
155. Wu L et al. *In vivo* and *in vitro* antiviral activity of hyperoside extracted from *Abelmoschus manihot* (L) medik. *Acta Pharmacol Sin* 2007; 28(3):404-9.
156. Butterweck V et al. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. *Planta Med* 2003; 69(3):189-92.
157. Benavente-García O and J Castillo. Update on uses and properties of *Citrus* flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. *J Agric Food Chem* 2008; 56(15):6185-205.
158. Young G and D Jewell. Interventions for varicosities and leg oedema in pregnancy. *Cochrane Database Syst Rev* 2000; (2):CD001066.
159. Wurglics M and M Schubert-Zsilavec. *Hypericum perforatum*: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. *Clin Pharmacokinet* 2006; 45(5):449-68.
160. Dubey A et al. *Ginkgo biloba*--an appraisal. *Kathmandu Univ Med J (KUMJ)* 2004; 2(3):225-9.
161. Puppala D, C Gairola, and H Swanson. Identification of kaempferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation. *Carcinogenesis* 2007; 28(3):639-47.
162. Moutsatsou P. The spectrum of phytoestrogens in nature: our knowledge is expanding. *Hormones (Athens)* 2007; 6(3):173-93.
163. Koleckar V et al. Condensed and hydrolysable tannins as antioxidants influencing the health. *Mini Rev Med Chem* 2008; 8(5):436-47.
164. Bell C and S Hawthorne. Ellagic acid, pomegranate and prostate cancer -- a mini review. *J Pharm Pharmacol* 2008; 60(2):139-44.

165. Syed D, F Afaq, and H Mukhtar. Pomegranate derived products for cancer chemoprevention. *Semin Cancer Biol* 2007; 17(5):377-85.
166. Lansky E and R Newman. *Punica granatum* (pomegranate) and its potential for prevention and treatment of inflammation and cancer. *J Ethnopharmacol* 2007; 109(2):177-206.
167. Mämmelä P et al. Analysis of oak tannins by liquid chromatography-electrospray ionisation mass spectrometry. *J Chromatogr A* 2000; 891(1):75-83.
168. Fukuda T, H Ito, and T Yoshida. Antioxidative polyphenols from walnuts (*Juglans regia* L.). *Phytochemistry* 2003; 63(7):795-801.
169. Chusri S and S Voravuthikunchai. *Quercus infectoria*: a candidate for the control of methicillin-resistant *Staphylococcus aureus* infections. *Phytother Res* 2008; 22(4):560-2.
170. Voravuthikunchai S and S Suwalak. Antibacterial activities of semipurified fractions of *Quercus infectoria* against enterohemorrhagic *Escherichia coli* O157:H7 and its verocytotoxin production. *J Food Prot* 2008; 71(6):1223-7.
171. Kaur G et al. Anti-inflammatory evaluation of alcoholic extract of galls of *Quercus infectoria*. *J Ethnopharmacol* 2004; 90(2-3):285-92.
172. Nandakumar V, T Singh, and S Katiyar. Multi-targeted prevention and therapy of cancer by proanthocyanidins. *Cancer Lett* 2008; 269(2):378-87.
173. Cos P et al. Proanthocyanidins in health care: current and new trends. *Curr Med Chem* 2004; 11(10):1345-59.
174. Aron P and J Kennedy. Flavan-3-ols: nature, occurrence and biological activity. *Mol Nutr Food Res* 2008; 52(1):79-104.
175. McKay D and J Blumberg. Cranberries (*Vaccinium macrocarpon*) and cardiovascular disease risk factors. *Nutr Rev* 2007; 65(11):490-502.
176. Howell A. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. *Mol Nutr Food Res* 2007; 51(6):732-7.
177. Stangl V et al. Molecular targets of tea polyphenols in the cardiovascular system. *Cardiovasc Res* 2007; 73(2):348-58.
178. Belz L et al. Mechanisms of cancer prevention by green and black tea polyphenols. *Anticancer Agents Med Chem* 2006; 6(5):389-406.
179. Friedman M. Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. *Mol Nutr Food Res* 2007; 51(1):116-34.
180. Oberdörster E et al. Common phytochemicals are ecdysteroid agonists and antagonists: a possible evolutionary link between vertebrate and invertebrate steroid hormones. *J Steroid Biochem Mol Biol* 2001; 77(4-5):229-38.
181. Yuan J, J Wang, and X Liu. Metabolism of dietary soy isoflavones to equol by human intestinal microbiota--implications for health. *Mol Nutr Food Res* 2007; 51(7):765-81.
182. Duncan A et al. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2000; 9(6):581-6.

183. Vatanparast H and P Chilibeck. Does the effect of soy phytoestrogens on bone in postmenopausal women depend on the equol-producing phenotype? *Nutr Rev* 2007; 65(6 Pt 1):294-9.
184. Jackman K, O Woodman, and C Sobey. Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights. *Curr Med Chem* 2007; 14(26):2824-30.
185. Tomar R and R Shiao. Early life and adult exposure to isoflavones and breast cancer risk. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 2008; 26(2):113-73.
186. Tsuda H et al. Carcinogenesis and its modification by environmental endocrine disruptors: *in vivo* experimental and epidemiological findings. *Jpn J Clin Oncol* 2003; 33(6):259-70.
187. Powles T et al. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. *Menopause Int* 2008; 14(1):6-12.
188. Cocchiello M et al. A review on usnic acid, an interesting natural compound. *Naturwissenschaften* 2002; 89(4):137-46.
189. Ingólfssdóttir K. Usnic acid. *Phytochemistry* 2002; 61(7):729-36.
190. Chang H and P But, Eds. 2000. *Pharmacology and Applications of Chinese Materia Medica*. Vol 1. Singapore: World Scientific. pp. 663-7.
191. Duarte J et al. Vasodilator effects of visnagin in isolated rat vascular smooth muscle. *Eur J Pharmacol* 1995; 286:115-22.
192. Fromming K et al. Influence of biopharmaceutical properties of drugs by natural occurring compounds as exemplified with khellin in an *Ammi visnaga* dry extract. *Pharm Ind* 1989; 51:439-43.
193. Valkova S, M Trashlieva, and P Christova. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. *Clin Exp Dermatol* 2004; 29(2):180-4.
194. Lieberman A et al. Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. *Parkinsonism Relat Disord* 2005; 11(2):81-4.
195. Inbaraj J and C Chignell. Cytotoxic action of juglone and plumbagin: a mechanistic study using HaCaT keratinocytes. *Chem Res Toxicol* 2004; 17(1):55-62.
196. Neri I et al. Acute irritant contact dermatitis due to *Juglans regia*. *Contact Dermatitis* 2006; 55(1):62-3.
197. Mikhaeil B et al. Antioxidant and immunomodulatory constituents of henna leaves. *Z Naturforsch [C]* 2004; 59(7-8):468-76.
198. Habbal O et al. In-vitro antimicrobial activity of *Lawsonia inermis* Linn (henna). A pilot study on the Omani henna. *Saudi Med J* 2005; 26(1):69-72.
199. Lemos T et al. Quinones from plants of northeastern Brazil: structural diversity, chemical transformations, NMR data and biological activities. *Nat Prod Res* 2007; 21(6):529-50.
200. Lira A et al. Development of lapachol topical formulation: anti-inflammatory study of a selected formulation. *AAPS PharmSciTech* 2008; 9(1):163-8.
201. Breger J et al. Antifungal chemical compounds identified using a *C. elegans* pathogenicity assay. *PLoS Pathog* 2007; 3(2):e18.

202. Bügel S. Vitamin K and bone health in adult humans. *Vitam Horm* 2008; 78:393-416.
203. Yoshida M et al. Phylloquinone intake, insulin sensitivity, and glycemic status in men and women. *Am J Clin Nutr* 2008; 88(1):210-5.
204. Wald A. Is chronic use of stimulant laxatives harmful to the colon? *J Clin Gastroenterol* 2003; 36(5):386-9.
205. Butterweck V and M Schmidt. St. John's wort: role of active compounds for its mechanism of action and efficacy. *Wien Med Wochenschr* 2007; 157(13-14):356-61.
206. Miskovsky P. Hypericin - a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. *Curr Drug Targets* 2002; 3(1):55-84.
207. Kubin A et al. Hypericin--the facts about a controversial agent. *Curr Pharm Des* 2005; 11(2):233-53.
208. Tagashira M, M Watanabe, and N Uemitsu. Antioxidative activity of hop bitter acids and their analogues. *Biosci Biotechnol Biochem* 1995; 59(4):740-2.
209. Hosking R and J Zajicek. Therapeutic potential of *Cannabis* in pain medicine. *Br J Anaesth* 2008; 101(1):59-68.
210. Robson P. Human studies of cannabinoids and medicinal *Cannabis*. *Handb Exp Pharmacol* 2005; (168):719-56.
211. Russo E and G Guy. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Med Hypotheses* 2006; 66(2):234-46.
212. Leweke F and D Koethe. *Cannabis* and psychiatric disorders: it is not only addiction. *Addict Biol* 2008; 13(2):264-75.
213. Wang T et al. Adverse effects of medical cannabinoids: a systematic review. *CMAJ* 2008; 178(13):1669-78.
214. Sforcin J. Propolis and the immune system: a review. *J Ethnopharmacol* 2007; 113(1):1-14.
215. Khalil M. Biological activity of bee propolis in health and disease. *Asian Pac J Cancer Prev* 2006; 7(1):22-31.
216. Walgrave S, E Warshaw, and L Glesne. Allergic contact dermatitis from propolis. *Dermatitis* 2005; 16(4):209-15.

Chapter 9

References: Terpenoids

1. Komiya M, T Takeuchi, and E Harada. Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and DA activities in mice. *Behav Brain Res* 2006; 172(2):240-9.
2. Moss M et al. Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. *Int J Neurosci* 2003; 113(1):15-38.

3. Heuberger E et al. Effects of chiral fragrances on human autonomic nervous system parameters and self-evaluation. *Chem Senses* 2001; 26(3):281-92.
4. Goel N, H Kim, and R Lao. An olfactory stimulus modifies nighttime sleep in young men and women. *Chronobiol Int* 2005; 22(5):889-904.
5. Shen J et al. Olfactory stimulation with scent of lavender oil affects autonomic nerves, lipolysis and appetite in rats. *Neurosci Lett* 2005; 383(1-2):188-93.
6. Anderson I et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. *Ann Intern Med* 1996; 124(8):726-34.
7. Perry N et al. Essential oils from Dalmatian sage (*Salvia officinalis* L.): variations among individuals, plant parts, seasons, and sites. *J Agric Food Chem* 1999; 47(5):2048-54.
8. Lachenmeier D et al. Absinthe - a review. *Crit Rev Food Sci Nutr* 2006; 46:365-77.
9. Naser B et al. *Thuja occidentalis* (Arbor vitae): A review of its pharmaceutical, pharmacological and clinical properties. *Evid Based Complement Alternat Med* 2005; 2(1):69-78.
10. Rohloff J, R Mordal, and S Dragland. Chemotypical variation of tansy (*Tanacetum vulgare* L.) from 40 different locations in Norway. *J Agric Food Chem* 2004; 52(6):1742-8.
11. Orav A, E Arak, and A Raal. Phytochemical analysis of the essential oil of *Achillea millefolium* L. from various European Countries. *Nat Prod Res* 2006; 20(12):1082-8.
12. Höld K et al. Alpha-thujone (the active component of absinthe): gamma-aminobutyric acid type A receptor modulation and metabolic detoxification. *Proc Natl Acad Sci U S A* 2000; 97(8):3826-31.
13. Dettling A et al. Absinthe: attention performance and mood under the influence of thujone. *J Stud Alcohol* 2004; 65(5):573-81.
14. Teixeira da Silva J. Mining the essential oils of the Anthemideae. *Afr J Biotechnol* 2004; 3:706-20.
15. Lachenmeier D et al. Chemical composition of vintage preban absinthe with special reference to thujone, fenchone, pinocamphone, methanol, copper, and antimony concentrations. *J Agric Food Chem* 2008; 56(9):3073-81.
16. Meschler J and A Howlett. Thujone exhibits low affinity for cannabinoid receptors but fails to evoke cannabimimetic responses. *Pharmacol Biochem Behav* 1999; 62(3):473-80.
17. Burt S. Essential oils: their antibacterial properties and potential applications in foods--a review. *Int J Food Microbiol* 2004; 94(3):223-53.
18. Basch E et al. Thyme (*Thymus vulgaris* L.), thymol. *J Herb Pharmacother* 2004; 4(1):49-67.
19. Nostro A et al. Susceptibility of methicillin-resistant staphylococci to oregano essential oil, carvacrol and thymol. *FEMS Microbiol Lett* 2004; 230(2):191-5.
20. Ashour H et al. Antibacterial, antifungal, and anticancer activities of volatile oils and extracts from stems, leaves, and flowers of *Eucalyptus sideroxylon* and *Eucalyptus torquata*. *Cancer Biol Ther* 2008; 7(3):399-403.

21. Cermellia C et al. Effect of eucalyptus essential oil on respiratory bacteria and viruses. *Curr Microbiol* 2008; 56(1):89-92.
22. Hong E et al. Antibacterial and antifungal effects of essential oils from coniferous trees. *Biol Pharm Bull* 2004; 27(6):863-6.
23. Crowell P, A Siar Ayoubi, and Y Burke. Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. *Adv Exp Med Biol* 1996; 401:131-6.
24. Lu X et al. Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene. *World J Gastroenterol* 2004; 10(14):2140-4.
25. Sun J. D-Limonene: safety and clinical applications. *Altern Med Rev* 2007; 12(3):259-64.
26. Brudnak M. Cancer-preventing properties of essential oil monoterpenes D-limonene and perillyl alcohol. <http://www.positivehealth.com/article-abstract.php?articleid=353>. Accessed September 22, 2008.
27. Hung J et al. Antiproliferative activity of aucubin is through cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells. *Clin Exp Pharmacol Physiol* 2008; 35(9):995-1001.
28. Chang I. Liver-protective activities of aucubin derived from traditional oriental medicine. *Res Commun Mol Pathol Pharmacol* 1998; 102(2):189-204.
29. Xue H et al. Neuroprotection of aucubin in primary diabetic encephalopathy. *Sci China C Life Sci* 2008; 51(6):495-502.
30. Jin L et al. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. *Eur J Pharmacol* 2008; 582(1-3):162-7.
31. Shim K et al. Effects of aucubin on the healing of oral wounds. *In Vivo* 2007; 21(6):1037-41.
32. Klun J, A Khrimian, and M Debboun. Repellent and deterrent effects of SS220, Picaridin, and Deet suppress human blood feeding by *Aedes aegypti*, *Anopheles stephensi*, and *Phlebotomus papatasi*. *J Med Entomol* 2006; 43(1):34-9.
33. Chen L et al. Down-regulation of NR2B receptors partially contributes to analgesic effects of gentiopicroside in persistent inflammatory pain. *Neuropharmacology* 2008; 54(8):1175-81.
34. Rojas A et al. Smooth muscle relaxing activity of gentiopicroside isolated from *Gentiana spathacea*. *Planta Med* 2000; 66(8):765-7.
35. Oztürk N et al. Effects of gentiopicroside, sweroside and swertiamarine, secoiridoids from gentian (*Gentiana lutea* ssp. *symphyandra*), on cultured chicken embryonic fibroblasts. *Planta Med* 2006; 72(4):289-94.
36. McKay D and J Blumberg. A review of the bioactivity and potential health benefits of chamomile tea (*Matricaria recutita* L.). *Phytother Res* 2006; 20(7):519-30.
37. Ramadan M et al. Chamazulene carboxylic acid and matricin: a natural prophen and its natural prodrug, identified through similarity to synthetic drug substances. *J Nat Prod* 2006; 69(7):1041-5.

38. Darra E et al. Insight into the apoptosis-inducing action of alpha-bisabolol towards malignant tumor cells: Involvement of lipid rafts and Bid. *Arch Biochem Biophys* 2008; 476(2):113-23.
39. Ganzera M, P Schneider, and H Stuppner. Inhibitory effects of the essential oil of chamomile (*Matricaria recutita* L.) and its major constituents on human cytochrome P450 enzymes. *Life Sci* 2006; 78(8):856-61.
40. Thomet O and H Simon. Petasins in the treatment of allergic diseases: results of preclinical and clinical studies. *Int Arch Allergy Immunol* 2002; 129(2):108-12.
41. Agosti R et al. Effectiveness of *Petasites hybridus* preparations in the prophylaxis of migraine: a systematic review. *Phytomedicine* 2006; 13(9-10):743-6.
42. Ríos J and M Recio. Medicinal plants and antimicrobial activity. *J Ethnopharmacol* 2005; 100(1-2):80-4.
43. Barrera P et al. Natural sesquiterpene lactones are active against *Leishmania mexicana*. *J Parasitol* 2008; Epub Mar 11:1, 18576826.
44. Zhang S et al. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. *Curr Med Chem Anticancer Agents* 2005; 5(3):239-49.
45. Benedek B et al. Yarrow (*Achillea millefolium* L. s.l.): pharmaceutical quality of commercial samples. *Pharmazie* 2008; 63(1):23-6.
46. Kuhn T and Y Wang. Artemisinin - an innovative cornerstone for anti-malaria therapy. *Prog Drug Res* 2008; 66(383):385-422.
47. Nakase I et al. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. *Int J Pharm* 2008; 354(1-2):28-33.
48. Pajak B, A Orzechowski, and B Gajkowska. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. *Folia Histochem Cytobiol* 2008; 46(2):129-35.
49. Benner M and H Lee. Anaphylactic reaction to chamomile tea. *J Allergy Clin Immunol* 1973; 52(5):307-8.
50. Warshaw E and K Zug. Sesquiterpene lactone allergy. *Am J Contact Dermat* 1996; 7(1):1-23.
51. Fraternali D et al. Essential oil composition and antioxidant activity of aerial parts of *Grindelia robusta* from Central Italy. *Fitoterapia* 2007; 78(6):443-5.
52. Kreutzer S, O Schimmer, and R Waibel. Triterpenoid saponin in the genus *Grindelia*. *Planta Med* 1990; 56(4):392-4.
53. Wellwood C and R Cole. Relevance of carnosic acid concentrations to the selection of rosemary, *Rosmarinus officinalis* (L.), accessions for optimization of antioxidant yield. *J Agric Food Chem* 2004; 52(20):6101-7.
54. Poeckel D et al. Carnosic acid and carnosol potently inhibit human 5-lipoxygenase and suppress pro-inflammatory responses of stimulated human polymorphonuclear leukocytes. *Biochem Pharmacol* 2008; 76(1):91-7.

55. Johnson J et al. Carnosol, a dietary diterpene, displays growth inhibitory effects in human prostate cancer PC3 cells leading to G(2)-phase cell cycle arrest and targets the 5'-AMP-activated protein kinase (AMPK) pathway. *Pharm Res* 2008; 25(9):2125-34.
56. Moran A et al. Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse. *Cancer Res* 2005; 65(3):1097-104.
57. Huang S et al. Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappa B and c-Jun. *Biochem Pharmacol* 2005; 69(2):221-32.
58. Singletary K, C MacDonald, and M Wallig. Inhibition by rosemary and carnosol of 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and *in vivo* DMBA-DNA adduct formation. *Cancer Lett* 1996; 104(1):43-8.
59. Dörrie J, K Sapala, and S Zunino. Carnosol-induced apoptosis and downregulation of Bcl-2 in B-lineage leukemia cells. *Cancer Lett* 2001; 170(1):33-9.
60. Xia S and D Fang. Pharmacological action and mechanisms of ginkgolide B. *Chin Med J (Engl)* 2007; 120(10):922-8.
61. Meade C and H Heuer. PAF antagonism as an approach to the treatment of airway hyperreactivity. *Am Rev Respir Dis* 1991; 143(3 Pt 2):S79-82.
62. Strømgaard K and K Nakanishi. Chemistry and biology of terpene trilactones from *Ginkgo biloba*. *Angew Chem Int Ed Engl* 2004; 43(13):1640-58.
63. Gotaskie G and B Andreassi. Paclitaxel: a new antimitotic chemotherapeutic agent. *Cancer Pract* 1994; 2(1):27-33.
64. Gunduz A et al. Clinical review of grayanotoxin/mad honey poisoning past and present. *Clin Toxicol (Phila)* 2008; 46(5):437-42.
65. Vincentz F. 2006. Research into *Euphorbia* latex and irritant ingredients. In: *Succulent Euphorbias*. http://www.euphorbia.de/giftig_e.htm. Accessed September 22, 2008.
66. Liu J et al. Oleanolic acid and ursolic acid: research perspectives. *J Ethnopharmacol* 2005; 100(1-2):92-4.
67. Sultana N and A Ata. Oleanolic acid and related derivatives as medicinally important compounds. *J Enzyme Inhib Med Chem* 2008; Epub Jul 10, 18618318.
68. Yin M and K Chan. Nonenzymatic antioxidative and antiglycative effects of oleanolic acid and ursolic acid. *J Agric Food Chem* 2007; 55(17):7177-81.
69. Sato H et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from *Olea europaea*. *Biochem Biophys Res Commun* 2007; 362(4):793-8.
70. Düker E et al. Effects of extracts from *Cimicifuga racemosa* on gonadotropin release in menopausal women and ovariectomized rats. *Planta Med* 1991; 57(5):420-4.
71. Einbond L et al. Growth inhibitory activity of extracts and compounds from *Cimicifuga* species on human breast cancer cells. *Phytomedicine* 2008; 15(6-7):504-11.
72. Onorato J and J Henion. Evaluation of triterpene glycoside estrogenic activity using LC/MS and immunoaffinity extraction. *Anal Chem* 2001; 73(19):4704-10.

73. Sakurai N et al. Anti-AIDS agents. Part 57: Actein, an anti-HIV principle from the rhizome of *Cimicifuga racemosa* (black cohosh), and the anti-HIV activity of related saponins. *Bioorg Med Chem Lett* 2004; 14(5):1329-32.
74. Esser K, K Semagn, and L Wolde-Yohannes. Medicinal use and social status of the soap berry endod (*Phytolacca dodecandra*) in Ethiopia. *J Ethnopharmacol* 2003; 85(2-3):269-77.
75. Sirtori C. Aescin: pharmacology, pharmacokinetics and therapeutic profile. *Pharmacol Res* 2001; 44(3):183-93.
76. Fiore C et al. Antiviral effects of *Glycyrrhiza* species. *Phytother Res* 2008; 22(2):141-8.
77. Negi A et al. Recent advances in plant hepatoprotectives: A chemical and biological profile of some important leads. *Med Res Rev* 2007; 28(5):746-72.
78. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. *Yakugaku Zasshi* 2000; 120(10):849-62.
79. Isbrucker R and G Burdock. Risk and safety assessment on the consumption of Licorice root (*Glycyrrhiza* spp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. *Regul Toxicol Pharmacol* 2006; 46(3):167-92.
80. Deyama T, S Nishibe, and Y Nakazawa. Constituents and pharmacological effects of *Eucommia* and Siberian ginseng. *Acta Pharmacol Sin* 2001; 22(12):1057-70.
81. Kimura Y and M Sumiyoshi. Effects of various *Eleutherococcus senticosus* cortex on swimming time, natural killer activity and corticosterone level in forced swimming stressed mice. *J Ethnopharmacol* 2004; 95(2-3):447-53.
82. Tohda C et al. Inhibitory effects of *Eleutherococcus senticosus* extracts on amyloid beta(25-35)-induced neuritic atrophy and synaptic loss. *J Pharmacol Sci* 2008; 107(3):329-39.
83. Lee T et al. Radioprotective potential of ginseng. *Mutagenesis* 2005; 20(4):237-43.
84. Nah S, D Kim, and H Rhim. Ginsenosides: are any of them candidates for drugs acting on the central nervous system? *CNS Drug Rev* 2007; 13(4):381-404.
85. Cheng Y, L Shen, and J Zhang. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. *Acta Pharmacol Sin* 2005; 26(2):143-9.
86. Laveaga G. Uncommon trajectories: steroid hormones, Mexican peasants, and the search for a wild yam. *Stud Hist Philos Biol Biomed Sci* 2005; 36(4):743-60.
87. Komesaroff P et al. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. *Climacteric* 2001; 4(2):144-50.
88. Dinchev D et al. Distribution of steroidal saponins in *Tribulus terrestris* from different geographical regions. *Phytochemistry* 2008; 69(1):176-86.
89. Gauthaman K and A Ganesana. The hormonal effects of *Tribulus terrestris* and its role in the management of male erectile dysfunction--an evaluation using primates, rabbit and rat. *Phytomedicine* 2008; 15(1-2):44-54.

90. Al-Bayati F and H Al-Mola. Antibacterial and antifungal activities of different parts of *Tribulus terrestris* L. growing in Iraq. *J Zhejiang Univ Sci B* 2008; 9(2):154-9.
91. Anon. *Ruscus aculeatus* (butcher's broom). Monograph. *Altern Med Rev* 2001; 6(6):608-12.
92. Kou J et al. Antithrombotic activities of aqueous extract from *Radix Ophiopogon japonicus* and its two constituents. *Biol Pharm Bull* 2006; 29(6):1267-70.
93. Felter H and J Lloyd. 1898. *Phytolacca* Monograph. In: *King's American Dispensatory*. Online: <http://www.henriettesherbal.com/eclectic/kings/phytolacca.htm>. Accessed September 22, 2008.
94. Wang T, J Fang, and Q-Y Zheng. Inhibitory effect of esculentoside A on prostaglandin E2 production from murine peritoneal macrophages and rabbit synovial cells *in vitro*. *Mediators Inflamm* 1997; 6(1):22-4.
95. Wang L et al. Bioactive triterpene saponins from the roots of *Phytolacca americana*. *J Nat Prod* 2008; 71(1):35-40.
96. Lewis W and P Smith. Poke root herbal tea poisoning. *JAMA* 1979; 242(25):2759-60.
97. Hamilton R, R Shih, and R Hoffman. Mobitz type I heart block after pokeweed ingestion. *Vet Hum Toxicol* 1995; 37(1):66-7.
98. Wilt T et al. Beta-sitosterols for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2000; (2):CD001043.
99. Bradford P and A Awad. Phytosterols as anticancer compounds. *Mol Nutr Food Res* 2007; 51(2):161-70.
100. Plat J and R Mensink. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. *Am J Cardiol* 2005; 96(1A):15D-22D.
101. Becker M, D Staab, and K Von Bergmann. Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol. *J Pediatr* 1993; 122(2):292-6.
102. Schoner W and G Scheiner-Bobis. Endogenous and exogenous cardiac glycosides and their mechanisms of action. *Am J Cardiovasc Drugs* 2007; 7(3):173-89.
103. Chavey W et al. Pharmacologic management of heart failure caused by systolic dysfunction. *Am Fam Physician* 2008; 77(7):957-64.
104. Yarnell E and K Abascal. Botanicals for regulating heart rhythms. *Alt & Comp Ther* 2003; 9(3):125-9.
105. Kopp B and W Kubelka. New cardenolides from *Convallaria majalis*. *Planta Med* 1982; 45(8):195-202.
106. Felter H and J Lloyd. 1898. *Convallaria* (U.S.P.) Monograph. In: *King's American Dispensatory*. Online: <http://www.henriettesherbal.com/eclectic/kings/convallaria.html>. Accessed September 22, 2008.
107. Choi D et al. The positive inotropic effect of the aqueous extract of *Convallaria keiskei* in beating rabbit atria. *Life Sci* 2006; 79(12):1178-85.

108. Janeczko A and A Skoczowski. Mammalian sex hormones in plants. *Folia Histochem Cytobiol* 2005; 43(2):71-9.
109. Lansky E and R Newman. *Punica granatum* (pomegranate) and its potential for prevention and treatment of inflammation and cancer. *J Ethnopharmacol* 2007; 109(2):177-206.
110. Deng R et al. The hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump. *J Pharmacol Exp Ther* 2007; 320(3):1153-62.
111. Shishodia S and B Aggarwal. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. *J Biol Chem* 2004; 279(45):47148-58.
112. Shishodia S et al. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. *Biochem Pharmacol* 2007; 74(1):118-30.
113. Singh S et al. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. *Cancer Res* 2007; 67(15):7439-49.
114. Xiao D and S Singh. z-Guggulsterone, a constituent of Ayurvedic medicinal plant *Commiphora mukul*, inhibits angiogenesis *in vitro* and *in vivo*. *Mol Cancer Ther* 2008; 7(1):171-80.
115. Khachik F et al. Chemistry, distribution, and metabolism of tomato carotenoids and their impact on human health. *Exp Biol Med (Maywood)* 2002; 227(10):845-51.
116. Rao A and L Rao. Carotenoids and human health. *Pharmacol Res* 2007; 55(3):207-16.
117. Seren S et al. Lycopene in cancer prevention and treatment. *Am J Ther* 2008; 15(1):66-81.
118. Dahan K et al. Lycopene in the prevention of prostate cancer. *J Soc Integr Oncol* 2008; 6(1):29-36.
119. Wu W et al. Inhibitory effect of lycopene on PDGF-BB-induced signaling and migration in human dermal fibroblasts: a possible target for cancer. *Biochem Soc Trans* 2007; 35(Pt 5):1377-8.
120. Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. *New England Journal of Medicine* 1994; 330(15):1029-35.
121. Michaud D et al. Intake of specific carotenoids and risk of lung cancer in 2 prospective US cohorts. *Am J Clin Nutr* 2000; 72(4):990-7.
122. Murakoshi M et al. Potent preventive action of alpha-carotene against carcinogenesis: spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by alpha-carotene than by beta-carotene. *Cancer Res* 1992; 52(23):6583-7.

123. Hodisan T et al. Carotenoid composition of *Rosa canina* fruits determined by thin-layer chromatography and high-performance liquid chromatography. *J Pharm Biomed Anal* 1997; 16(3):521-8.
124. Pashkow F, D Watumull, and C Campbell. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. *Am J Cardiol* 2008; 101(10A):58D-68D.
125. Hussein G et al. Astaxanthin, a carotenoid with potential in human health and nutrition. *J Nat Prod* 2006; 69(3):443-9.
126. Chew B and J Park. Carotenoid action on the immune response. *J Nutr* 2004; 134(1):257S-261S.
127. World Health Organization. 2008. 635. *Canthaxanthin (WHO Food Additives Series 22)*. Online at INCHEM: <http://www.inchem.org/documents/jecfa/jecmono/v22je09.htm>. Accessed September 22, 2008.
128. Oshima S et al. Accumulation and clearance of capsanthin in blood plasma after the ingestion of paprika juice in men. *J Nutr* 1997; 127(8):1475-9.
129. Zhao L and B Sweet. Lutein and zeaxanthin for macular degeneration. *Am J Health Syst Pharm* 2008; 65(13):1232-8.
130. Czczuga-Semeniuk E and S Wolczynski. Identification of carotenoids in ovarian tissue in women. *Oncol Rep* 2005; 14(5):1385-92.
131. Gyémánt N et al. Reversal of multidrug resistance of cancer cells *in vitro*: modification of drug resistance by selected carotenoids. *Anticancer Res* 2006; 26(1A):367-74.
132. Ochs-Balcom H et al. Antioxidants, oxidative stress, and pulmonary function in individuals diagnosed with asthma or COPD. *Eur J Clin Nutr* 2006; 60(8):991-9.
133. Lian F et al. Beta-cryptoxanthin suppresses the growth of immortalized human bronchial epithelial cells and non-small-cell lung cancer cells and up-regulates retinoic acid receptor beta expression. *Int J Cancer* 2006; 119(9):2084-9.
134. Loane E et al. Transport and retinal capture of lutein and zeaxanthin with reference to age-related macular degeneration. *Surv Ophthalmol* 2008; 53(1):68-81.
135. Schünemann H et al. Lung function in relation to intake of carotenoids and other antioxidant vitamins in a population-based study. *Am J Epidemiol* 2002; 155(5):463-71.
136. Escribano J et al. Crocin, safranal and picrocrocin from saffron (*Crocus sativus* L.) inhibit the growth of human cancer cells *in vitro*. *Cancer Lett* 1996; 100(1-2):23-30.
137. Abe K and H Saito. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. *Phytother Res* 2000; 14(3):149-52.

Chapter 10

References: Alkaloids

1. Stozkowska W. Evaluation of Cepen cream after 15 years of treatment of burn scars. *Przegl Lek* 2002; 59(12):1028-30.
2. Willital G and H Heine. Efficacy of Contractubex gel in the treatment of fresh scars after thoracic surgery in children and adolescents. *Int J Clin Pharmacol Res* 1994; 14(5-6):193-202.
3. Ferré S. An update on the mechanisms of the psychostimulant effects of caffeine. *J Neurochem* 2008; 105(4):1067-79.
4. Bolignano D et al. Caffeine and the kidney: what evidence right now? *J Ren Nutr* 2007; 17(4):225-34.
5. Spencer B. Caffeine withdrawal: a model for migraine? *Headache* 2002; 42(6):561-2.
6. Magkos F and S Kavouras. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. *Sports Med* 2004; 34(13):871-89.
7. Strachan E and A Bennett. Theobromine poisoning in dogs. *Vet Rec* 1994; 134(11):284.
8. Molfino N and P Zhang. A meta-analysis on the efficacy of oral theophylline in patients with stable COPD. *Int J Chron Obstruct Pulmon Dis* 2006; 1(3):261-6.
9. Hansel T et al. Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease. *Drugs Today (Barc)* 2004; 40(1):55-69.
10. Horner N and J Lampe. Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. *J Am Diet Assoc* 2000; 100(11):1368-80.
11. Phelps H and C Phelps. Caffeine ingestion and breast cancer. A negative correlation. *Cancer* 1988 Mar; 61(5):1051-4.
12. Zou D et al. Cactus pear: a natural product in cancer chemoprevention. *Nutr J* 2005; 4:25.
13. Tesoriere L et al. Distribution of betalain pigments in red blood cells after consumption of cactus pear fruits and increased resistance of the cells to ex vivo induced oxidative hemolysis in humans. *J Agric Food Chem* 2005; 53(4):1266-70.
14. Kanner J, S Harel, and R Granit. Betalains--a new class of dietary cationized antioxidants. *J Agric Food Chem* 2001; 49(11):5178-85.
15. Cai Y, M Sun, and H Corke. Antioxidant activity of betalains from plants of the Amaranthaceae. *J Agric Food Chem* 2003; 51(8):2288-94.
16. Agarwal M et al. Hepatoprotective activity of *Beta vulgaris* against CCl₄-induced hepatic injury in rats. *Fitoterapia* 2006; 77(2):91-3.
17. Kapadia G et al. Chemoprevention of lung and skin cancer by *Beta vulgaris* (beet) root extract. *Cancer Lett* 1996; 100(1-2):211-4.
18. Kapadia G et al. Chemoprevention of DMBA-induced UV-B promoted, NOR-1-induced TPA promoted skin carcinogenesis, and DEN-induced phenobarbital promoted liver tumors in mice by extract of beetroot. *Pharmacol Res* 2003; 47(2):141-8.

19. Roeder E. Medicinal plants in China containing pyrrolizidine alkaloids. *Pharmazie* 2000; 55(10):711-26.
20. Australia New Zealand Food Authority. 2001. *Pyrrolizidine alkaloids in food: a toxicological review and risk assessment*. Technical Report Series No 2. Online: http://www.foodstandards.gov.au/_srcfiles/TR2.pdf. Accessed September 22, 2008.
21. Fu P et al. Pyrrolizidine alkaloids - genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. *Drug Metab Rev* 2004; 36(1):1-55.
22. Ma et al. Pyrrole-protein adducts - A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity. *J Food Drug Anal* 2018; Jul;26(3):965-972.
23. Cheeke P. Toxicity and metabolism of pyrrolizidine alkaloids. *J Anim Sci* 1988; 66(9):2343-50.
24. Stickel F and H Seitz. The efficacy and safety of comfrey. *Public Health Nutr* 2000; 3(4A):501-8.
25. Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. *Pharmazie* 1995; 50(2):83-98.
26. Habs et al. A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions. *Nutrients* 2017; Jul 7;9(7).
27. Sperl W et al. Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea. *Eur J Pediatr* 1995; 154(2):112-6.
28. Kälin P. The common butterbur (*Petasites hybridus*) - portrait of a medicinal herb. *Forsch Komplementarmed Klass Naturheilkd* 2003; 10 Suppl 1:41-4.
29. Barna M et al. Wound healing effects of a *Symphytum* herb extract cream (*Symphytum x uplandicum* NYMAN): results of a randomized, controlled double-blind study. *Wien Med Wochenschr* 2007; 157(21-22):569-74.
30. Roeder 1995.
31. D'Anchise R, M Bulitta, and B Giannetti. Comfrey extract ointment in comparison to diclofenac gel in the treatment of acute unilateral ankle sprains (distortions). *Arzneimittelforschung* 2007; 57(11):712-6.
32. Roeder 1995.
33. Hirono I, H Mori, and C Culvenor. Carcinogenic activity of coltsfoot, *Tussilago farfara* L. *Gann* 1976; 67(1):125-9.
34. Rosenthal M, B Vishwanath, and R Franson. Effects of aristolochic acid on phospholipase A2 activity and arachidonate metabolism of human neutrophils. *Biochim Biophys Acta* 1989; 1001(1):1-8.
35. Cosyns J. Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. *Drug Saf* 2003; 26(1):33-48.
36. Arlt V et al. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. *Carcinogenesis* 2007; 28(11):2253-61.

37. Long D and T Voice. Role of exposure analysis in solving the mystery of Balkan endemic nephropathy. *Croat Med J* 2007; 48(3):300-11.
38. O'Brien P, C Carrasco-Pozo, and H Speisky. Boldine and its antioxidant or health-promoting properties. *Chem Biol Interact* 2006; 159(1):1-17.
39. Lau et al. Boldine Ameliorates Vascular Oxidative Stress and Endothelial Dysfunction: Therapeutic Implication for Hypertension and Diabetes. *J Cardiovasc Pharmacol* 2015; Jun;65(6):522-31.
40. Almeida E, A Melo, and H Xavier. Toxicological evaluation of the hydro-alcohol extract of the dry leaves of *Peumus boldus* and boldine in rats. *Phytother Res* 2000; 14(2):99-102.
41. Gafner S et al. Alkaloids from *Eschscholzia californica* and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors *in vitro*. *J Nat Prod* 2006; 69(3):432-5.
42. Fedurco et al. Modulatory Effects of *Eschscholzia californica* Alkaloids on Recombinant GABAA Receptors. *Biochem Res Int* 2015; 2015:617620.
43. Lee C et al. Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. *Pharmacol Res* 2007; 56(3):193-201.
44. Pandey M et al. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. *Cancer Res* 2008; 68(13):5370-9.
45. Rohrer U et al. Antimicrobial activity of *Mahonia aquifolium* and two of its alkaloids against oral bacteria. *Schweiz Monatsschr Zahnmed* 2007; 117(11):1126-31.
46. Mahady G et al. *In vitro* susceptibility of *Helicobacter pylori* to isoquinoline alkaloids from *Sanguinaria canadensis* and *Hydrastis canadensis*. *Phytother Res* 2003; 17(3):217-21.
47. Sriwilajareon N et al. Stage specificity of *Plasmodium falciparum* telomerase and its inhibition by berberine. *Parasitol Int* 2002; 51(1):99-103.
48. Kaneda Y et al. *In vitro* effects of berberine sulphate on the growth and structure of *Entamoeba histolytica*, *Giardia lamblia* and *Trichomonas vaginalis*. *Ann Trop Med Parasitol* 1991; 85(4):417-25.
49. Freile M et al. Antimicrobial activity of aqueous extracts and of berberine isolated from *Berberis heterophylla*. *Fitoterapia* 2003; 74(7-8):702-5.
50. Lau C et al. Cardiovascular actions of berberine. *Cardiovasc Drug Rev* 2001; 19(3):234-44.
51. Yin J, H Xing, and J Ye. Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism* 2008; 57(5):712-7.
52. Liu W et al. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. *Chin Med J* 2008; 121(8):706-12.

53. Bagade, A, V. Tumbigeremutt and G. Pallavi. Effects of Berberine: A Review of the Literature. *Journal of Restorative Medicine* 2017; 6: 37.
54. Jiang et al. Therapeutic potential of berberine against neurodegenerative diseases. *Sci China Life Sci* 2015; 58(6): 564-569.
55. Neag et al. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. *Front Pharmacol* 2018; Aug 21;9:557.
56. Chen et al. The effect of berberine hydrochloride on *Enterococcus faecalis* biofilm formation and dispersion in vitro. *Microbiol Res* 2016; May-Jun;186-187:44-51.
57. Felter H and J Lloyd. 1898. Hydrastis (U.S.P.) Monograph. In: *King's American Dispensatory*. Online: <https://www.henriettes-herb.com/eclectic/kings/hydrastis.html>. Accessed September 6, 2019.
58. Slobodníková L et al. Antimicrobial activity of *Mahonia aquifolium* crude extract and its major isolated alkaloids. *Phytother Res* 2004; 18(8):674-6.
59. Zhu X. Development of natural products as drugs acting on central nervous system. *Mem Inst Oswaldo Cruz* 1991; 86 Suppl 2:173-5.
60. Yang Z et al. Medication of l-tetrahydropalmatine significantly ameliorates opiate craving and increases the abstinence rate in heroin users: a pilot study. *Acta Pharmacol Sin* 2008; 29(7):781-8.
61. Song L et al. Electrophysiological effects of protopine in cardiac myocytes: inhibition of multiple cation channel currents. *Br J Pharmacol* 2000; 129(5):893-900.
62. Rathi A et al. Hepatoprotective potential of *Fumaria indica* Pugsley whole plant extracts, fractions and an isolated alkaloid protopine. *Phytomedicine* 2008; 15(6-7):470-7.
63. Hiller K, M Ghorbani, and H Schilcher. Antispasmodic and relaxant activity of chelidonine, protopine, coptisine, and *Chelidonium majus* extracts on isolated guinea-pig ileum. *Planta Med* 1998; 64(8):758-60.
64. Mackraj I, T Govender, and P Gathiram. Sanguinarine. *Cardiovasc Ther* 2008; 26(1):75-83.
65. Tenenbaum H, M Dahan, and M Soell. Effectiveness of a sanguinarine regimen after scaling and root planing. *J Periodontol* 1999; 70(3):307-11.
66. Malikova J, A Zdarilova, and A Hlobilkova. Effects of sanguinarine and chelerythrine on the cell cycle and apoptosis. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2006; 150(1):5-12.
67. Vetter J. Poison hemlock (*Conium maculatum* L.). *Food Chem Toxicol* 2004; 42(9):1373-82.
68. Felter H and J Lloyd. 1898. Conium (U.S.P.) Monograph. In: *King's American Dispensatory*. Online: <http://www.henriettesherbal.com/eclectic/kings/conium.html>. September 22, 2008.
69. Stead L and J Hughes. Lobeline for smoking cessation. *Cochrane Database Syst Rev* 2000; (2):CD000124.

70. Dwoskin L and P Crooks. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. *Biochem Pharmacol* 2002; 63(2):89-98.
71. Van Noordwijk J and U Hollstein. The anthelmintic activity of pelletierine and isopelletierine. *Acta Physiol Pharmacol Neerl* 1956; 5(2):212-3.
72. Singh et al. An appraisal of the bioavailability enhancers in Ayurveda in the light of recent pharmacological advances. *Ayu* 2016; Jan-Mar;37(1):3-10.
73. Manayi et al. Piperine as a Potential Anti-cancer Agent: A Review on Preclinical Studies. *Curr Med Chem* 2018; 25(37):4918-4928.
74. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. *Crit Rev Food Sci Nutr* 2007; 47(8):735-48.
75. Das G. Therapeutic review. Cardiac effects of atropine in man: an update. *Int J Clin Pharmacol Ther Toxicol* 1989; 27(10):473-7.
76. Renner U, R Oertel, and W Kirch. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. *Ther Drug Monit* 2005; 27(5):655-65.
77. Felter H and J Lloyd. 1898. Stramonium Monograph. In: *King's American Dispensatory*. Online: <http://www.henriettesherbal.com/eclectic/felter/datura.html>. Accessed September 22, 2008.
78. Lee M. Solanaceae IV: *Atropa belladonna*, deadly nightshade. *J R Coll Physicians Edinb* 2007; 37(1):77-84.